EC Number |
Recommended Name |
Source Tissue |
Reference |
---|
1.1.1.149 | 20alpha-hydroxysteroid dehydrogenase |
carcinoma cell |
breast cancer cells: tumorgenic strains MCF-7, MDA-MB-231, T-47D, nontumorgenic strain MCF-10A |
655129 |
1.1.1.205 | IMP dehydrogenase |
carcinoma cell |
- |
705494 |
1.1.1.205 | IMP dehydrogenase |
carcinoma cell |
type II isoform predominates |
705494 |
1.1.1.239 | 3alpha(17beta)-hydroxysteroid dehydrogenase (NAD+) |
carcinoma cell |
- |
711670 |
1.1.1.27 | L-lactate dehydrogenase |
carcinoma cell |
differential expressions of LDH isozymes in different types of tumors |
-, 685502 |
1.1.1.27 | L-lactate dehydrogenase |
carcinoma cell |
endometrial and ovarian |
683562 |
1.1.1.300 | NADP-retinol dehydrogenase |
carcinoma cell |
squamos cell carcinoma, SCC tumor |
656810 |
1.1.1.41 | isocitrate dehydrogenase (NAD+) |
carcinoma cell |
- |
741407 |
1.11.1.8 | iodide peroxidase |
carcinoma cell |
follicular carcinoma cell |
742347 |
1.13.11.31 | arachidonate 12-lipoxygenase |
carcinoma cell |
12-LOX is overexpressed in a variety of human tumors |
686330 |
1.13.11.31 | arachidonate 12-lipoxygenase |
carcinoma cell |
most tumors show constitutive overexpression of platelet-type mRNA, leukocyte-type specific transcripts are detectable only in a few tumors |
395426 |
1.13.11.34 | arachidonate 5-lipoxygenase |
carcinoma cell |
- |
690170 |
1.13.11.34 | arachidonate 5-lipoxygenase |
carcinoma cell |
of diverse tissues, e.g. colon, lung breast, prostate, pancreas, bone, brain, and mesothelial cancer cells |
686278 |
1.14.11.65 | [histone H3]-dimethyl-L-lysine9 demethylase |
carcinoma cell |
- |
755188 |
1.14.11.66 | [histone H3]-trimethyl-L-lysine9 demethylase |
carcinoma cell |
- |
745919, 752645 |
1.14.11.66 | [histone H3]-trimethyl-L-lysine9 demethylase |
carcinoma cell |
JMJD2A protein is overexpressed in several tumors |
745949 |
1.14.11.66 | [histone H3]-trimethyl-L-lysine9 demethylase |
carcinoma cell |
KDM4A is amplified and overexpressed in cancer cells of several tumor types |
753167 |
1.14.11.66 | [histone H3]-trimethyl-L-lysine9 demethylase |
carcinoma cell |
levels of KDM4B histone demethylase are elevated in different types of cancer cells |
725520 |
1.14.11.69 | [histone H3]-trimethyl-L-lysine36 demethylase |
carcinoma cell |
- |
745919, 752645 |
1.14.11.69 | [histone H3]-trimethyl-L-lysine36 demethylase |
carcinoma cell |
JMJD2A protein is overexpressed in several tumors |
745949 |
1.14.11.69 | [histone H3]-trimethyl-L-lysine36 demethylase |
carcinoma cell |
KDM4A is amplified and overexpressed in cancer cells of several tumor types |
753167 |
1.14.14.17 | squalene monooxygenase |
carcinoma cell |
- |
746530 |
1.14.15.6 | cholesterol monooxygenase (side-chain-cleaving) |
carcinoma cell |
epithelial ovarian carcinoma |
658388 |
1.14.16.4 | tryptophan 5-monooxygenase |
carcinoma cell |
- |
438664 |
1.14.99.66 | [histone H3]-N6,N6-dimethyl-L-lysine4 FAD-dependent demethylase |
carcinoma cell |
- |
755188 |
1.17.3.2 | xanthine oxidase |
carcinoma cell |
- |
686042 |
1.17.4.1 | ribonucleoside-diphosphate reductase |
carcinoma cell |
- |
688283 |
1.17.4.1 | ribonucleoside-diphosphate reductase |
carcinoma cell |
lung and colon cancer cell lines |
672909 |
1.17.4.1 | ribonucleoside-diphosphate reductase |
carcinoma cell |
squamous |
657780 |
1.2.1.104 | pyruvate dehydrogenase system |
carcinoma cell |
non-small cell lung carcinoma |
662948 |
1.21.99.4 | thyroxine 5'-deiodinase |
carcinoma cell |
hepatocellular carcinoma |
733218 |
1.3.1.1 | dihydropyrimidine dehydrogenase (NAD+) |
carcinoma cell |
cell line CAL 7 |
349143 |
1.3.1.1 | dihydropyrimidine dehydrogenase (NAD+) |
carcinoma cell |
cell line ORL 1 |
349142 |
1.3.1.2 | dihydropyrimidine dehydrogenase (NADP+) |
carcinoma cell |
cancer cell line CAL 7 |
349143 |
1.3.1.2 | dihydropyrimidine dehydrogenase (NADP+) |
carcinoma cell |
cancer cell line ORL 1 |
349142 |
1.3.1.20 | trans-1,2-dihydrobenzene-1,2-diol dehydrogenase |
carcinoma cell |
cisplatin-sensitive ovarian carcinoma cell line 2008 and its cisplatin-resistant variant 2008/C13* |
656043 |
1.3.1.20 | trans-1,2-dihydrobenzene-1,2-diol dehydrogenase |
carcinoma cell |
human oral epidermal carcinoma cell line OEC-M1, enzyme expression is induced by pretreatment with hydroxychavicol |
657392 |
1.3.1.20 | trans-1,2-dihydrobenzene-1,2-diol dehydrogenase |
carcinoma cell |
ovarian carcinoma cell A2780 and SKOV-3, cisplatin-sensitive and cisplatin-resistant cell 2008 and 2008/C13*, cervical carcinoma cell A431, germ-cell tumor Tera-2, lung adenocarcinoma cell Calu-6 |
655159 |
1.3.5.2 | dihydroorotate dehydrogenase (quinone) |
carcinoma cell |
colon cancer has a high expression of DHODH and HCT-116 is sensitive to DHODH inhibition, while DHODH is not overexpressed in pancreatic cancer |
763351 |
1.4.1.3 | glutamate dehydrogenase [NAD(P)+] |
carcinoma cell |
- |
763376 |
1.4.1.3 | glutamate dehydrogenase [NAD(P)+] |
carcinoma cell |
upregulation of hGDH1/2 expression occurs in cancer |
762783 |
1.5.1.15 | methylenetetrahydrofolate dehydrogenase (NAD+) |
carcinoma cell |
highly expressed in many cancer types |
756334 |
1.5.1.5 | methylenetetrahydrofolate dehydrogenase (NADP+) |
carcinoma cell |
highly expressed in many cancer types |
756334 |
1.5.3.16 | spermine oxidase |
carcinoma cell |
hepatocellular carcinoma cell |
764816 |
1.5.8.3 | sarcosine dehydrogenase |
carcinoma cell |
renal carcinoma cell |
765488 |
1.5.8.4 | dimethylglycine dehydrogenase |
carcinoma cell |
hepatocellular carcinoma |
743378 |
1.6.3.1 | NAD(P)H oxidase (H2O2-forming) |
carcinoma cell |
the cytosolic N-terminal segment, containing 4 calcium binding EF-hands is missing in Nox5S, a short calcium-insensitive variant, which is the dominant isoform in carcinoma cells, and expressed together with the long Nox5L in endothelial cells. Nox5S may be constitutively active or be a competitive inhibitor of calcium-dependent activation when present in the same tetrameric complex as Nox5L |
724778 |
1.8.98.2 | sulfiredoxin |
carcinoma cell |
- |
765246 |
2.1.1.1 | nicotinamide N-methyltransferase |
carcinoma cell |
- |
706094 |
2.1.1.1 | nicotinamide N-methyltransferase |
carcinoma cell |
papillary thyroid carcinoma cell |
662513 |
2.1.1.166 | 23S rRNA (uridine2552-2'-O)-methyltransferase |
carcinoma cell |
transcripts are abundant |
703879 |
2.1.1.233 | [phosphatase 2A protein]-leucine-carboxy methyltransferase |
carcinoma cell |
- |
756498 |
2.1.1.77 | protein-L-isoaspartate(D-aspartate) O-methyltransferase |
carcinoma cell |
PIMT levels are regulated by cell adhesion in various cancer cell lines. The upregulation of PIMT expression could be prevented by an anti-alphavbeta3 antibody (LM609) or by a cyclic RGD peptide (XJ735) specific to integrin alphavbeta3. PIMT expression returns to the basal level when cells are replated on a substratum after detachment, though downregulation of PIMT expression could be partly prevented by the PI3K inhibitors LY294002 and wortmannin, as well as by the proteasome inhibitors MG-132, lactacystin, and beta-lactone |
671815 |
2.1.2.3 | phosphoribosylaminoimidazolecarboxamide formyltransferase |
carcinoma cell |
- |
719415 |
2.2.1.1 | transketolase |
carcinoma cell |
- |
691270 |
2.2.1.1 | transketolase |
carcinoma cell |
papillary thyroid carcinoma with or without lymph-node metastases |
691583 |
2.3.1.135 | phosphatidylcholine-retinol O-acyltransferase |
carcinoma cell |
skin, these cells have lower LRAT activity |
638622 |
2.3.1.15 | glycerol-3-phosphate 1-O-acyltransferase |
carcinoma cell |
- |
756003 |
2.3.1.15 | glycerol-3-phosphate 1-O-acyltransferase |
carcinoma cell |
isozyme GPAT2 is highly expressed in several cancer types (such as lung, melanoma, breast, and prostate cancer) and cancer-derived human cell lines |
757868 |
2.3.1.23 | 1-acylglycerophosphocholine O-acyltransferase |
carcinoma cell |
Ehrlich ascites |
486617 |
2.3.1.50 | serine C-palmitoyltransferase |
carcinoma cell |
embryonic cell line PCC7-Mz1 |
487174 |
2.3.1.76 | retinol O-fatty-acyltransferase |
carcinoma cell |
squamous SCC12b and SCC13b lines are common type of skin cancer that has reduced capacity to esterify retinol relative to normal keratinocytes |
487496 |
2.3.1.85 | fatty-acid synthase system |
carcinoma cell |
mammary adenocarcinoma cell, expression of high levels of enzyme |
661434 |
2.3.1.B41 | protein-long-chain fatty-acyl-lysine deacylase (NAD+) |
carcinoma cell |
- |
756689 |
2.3.2.23 | E2 ubiquitin-conjugating enzyme |
carcinoma cell |
Ube2T is overexpressed in several cancers |
759600 |
2.3.2.24 | (E3-independent) E2 ubiquitin-conjugating enzyme |
carcinoma cell |
UBE2O expression in cell lines and cancers, and UBE2O expression and mutation in cancers, detailed overview |
759177 |
2.3.2.5 | glutaminyl-peptide cyclotransferase |
carcinoma cell |
- |
759031, 759839 |
2.4.1.102 | beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase |
carcinoma cell |
GCNT3 is elevated in skin and mesothelioma cells and in some lung and breast cancer cells |
759882 |
2.4.1.144 | beta-1,4-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase |
carcinoma cell |
- |
759316 |
2.4.1.174 | glucuronylgalactosylproteoglycan 4-beta-N-acetylgalactosaminyltransferase |
carcinoma cell |
- |
-, 759759 |
2.4.1.228 | lactosylceramide 4-alpha-galactosyltransferase |
carcinoma cell |
globo series-related genes, and in particular, A4GALT, are elevated in epithelial cancer cells and associated with improved patient's outcome |
758994 |
2.4.2.4 | thymidine phosphorylase |
carcinoma cell |
diverse cancer types, overview |
705495 |
2.4.2.4 | thymidine phosphorylase |
carcinoma cell |
the enzyme is highly upregulated in a variety of solid tumours |
759143 |
2.4.2.4 | thymidine phosphorylase |
carcinoma cell |
the enzyme is upregulated in many solid tumors |
702162 |
2.4.3.1 | beta-galactoside alpha-(2,6)-sialyltransferase |
carcinoma cell |
- |
759878 |
2.5.1.6 | methionine adenosyltransferase |
carcinoma cell |
hepatocellular carcinoma, MAT1A is replaced by MAT2A |
657503 |
2.6.1.16 | glutamine-fructose-6-phosphate transaminase (isomerizing) |
carcinoma cell |
- |
639908 |
2.6.1.42 | branched-chain-amino-acid transaminase |
carcinoma cell |
BCAT1 has been extensively reported in malignancies including gliomas, ovarian, colorectal, gastric cancer, nasoparyngeal carcinomas, breast cancer, and chronic myeloid leukemia (CML) |
758657 |
2.7.1.1 | hexokinase |
carcinoma cell |
the enzyme is expressed at high level in cancer cells compared with normal cells |
759210 |
2.7.1.127 | inositol-trisphosphate 3-kinase |
carcinoma cell |
- |
737402, 737593, 760540, 762015 |
2.7.1.137 | phosphatidylinositol 3-kinase |
carcinoma cell |
- |
688925, 707976 |
2.7.1.145 | deoxynucleoside kinase |
carcinoma cell |
- |
739211 |
2.7.1.153 | phosphatidylinositol-4,5-bisphosphate 3-kinase |
carcinoma cell |
- |
707977 |
2.7.1.32 | choline kinase |
carcinoma cell |
- |
758809, 759595 |
2.7.1.32 | choline kinase |
carcinoma cell |
ChoKalpha1 is upregulated in many tumor types, including breast, lung, colorectal, and prostate cancers |
760183 |
2.7.1.40 | pyruvate kinase |
carcinoma cell |
- |
761028, 761521, 761878 |
2.7.1.40 | pyruvate kinase |
carcinoma cell |
prevalence of dimeric PKM2 in cancer |
760578 |
2.7.1.48 | uridine/cytidine kinase |
carcinoma cell |
- |
758650, 758880 |
2.7.1.48 | uridine/cytidine kinase |
carcinoma cell |
UCK2 is differentially expressed in many cancer tissues and in cells subjected to viral infection |
758919 |
2.7.1.60 | N-acylmannosamine kinase |
carcinoma cell |
pancreatic |
722220 |
2.7.1.67 | 1-phosphatidylinositol 4-kinase |
carcinoma cell |
isozyme PI4KIIalpha expression is upregulated in many human cancers but is especially highly expressed in malignant melanoma, fibrosarcoma, breast cancer (non-specific infiltrating duct and infiltrating lobular carcinomas) bladder transitional cell carcinoma and thyroid papillary carcinoma |
721967 |
2.7.1.94 | acylglycerol kinase |
carcinoma cell |
- |
738754 |
2.7.10.2 | non-specific protein-tyrosine kinase |
carcinoma cell |
- |
490443, 490457 |
2.7.10.2 | non-specific protein-tyrosine kinase |
carcinoma cell |
hematopoietic and epithelial cancer cells |
490469 |
2.7.10.2 | non-specific protein-tyrosine kinase |
carcinoma cell |
p54rak is overexpressed in subsets of primary human epithelial tumors |
490442 |
2.7.11.2 | [pyruvate dehydrogenase (acetyl-transferring)] kinase |
carcinoma cell |
- |
721971, 723186 |
2.7.11.20 | elongation factor 2 kinase |
carcinoma cell |
- |
740015, 760308 |
2.7.11.21 | polo kinase |
carcinoma cell |
- |
740152 |
2.7.11.21 | polo kinase |
carcinoma cell |
increased requirement for Plk1 in comparison to normal cells |
679095 |
2.7.11.27 | [acetyl-CoA carboxylase] kinase |
carcinoma cell |
- |
741308 |